Molecular Medicine

, Volume 20, Issue 1, pp 559–568 | Cite as

C1q-Mediated Repression of Human Monocytes Is Regulated by Leukocyte-Associated Ig-Like Receptor 1 (LAIR-1)

  • Myoungsun Son
  • Betty Diamond
Research Article


Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by abnormal function of both the innate and the adaptive immune system, leading to a loss of tolerance to self-antigens. Monocytes are a key component of the innate immune system and are efficient producers of multiple cytokines. In SLE, inappropriate activation of monocytes is thought to contribute to the loss of self-tolerance. In this study, we demonstrate that type 1 interferon (IFN) production by CpG-challenged monocytes can be suppressed by C1q through activating leukocyte-associated Ig-like receptor-1 (LAIR-1), which contains immunoreceptor tyrosine-based inhibition motifs (ITIMs). The phosphorylation of LAIR-1 and the interaction of LAIR-1 with SH2 domain-containing protein tyrosine phosphatase-1 (SHP-1) were enhanced after LAIR-1 engagement by C1q. Moreover, engagement of LAIR-1 by C1q inhibited nuclear translocation of interferon regulatory factor (IRF)-3 and IRF5 in CpG-stimulated monocytes. These data suggest a model in which LAIR-1 engagement by C1q helps maintain monocyte tolerance, specifically with respect to Toll-like receptor-9-mediated monocyte activation.



This work was supported by National Institutes of Health Grant R01AR-049126 to B Diamond and an Arthritis Foundation Fellowship to M Son. We would like to thank Sylvia Jones for expert secretarial assistance and the flow cytometry and imaging cores of the Feinstein Institute for Medical Research and Barbara Sherry, Frances Santiago-Schwarz, Sun-Jung Kim and Yong-Rui Zou for review of the manuscript. We also thank Frances SantiagoSchwarz for initiating our studies of LAIR-1.


  1. 1.
    Katsiari CG, Liossis SN, Sfikakis PP. (2010) The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin. Arthritis Rheum. 39:491–503.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee PY, et al. (2008) A novel type I IFN-producing cell subset in murine lupus. J. Immunol. 180:5101–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Li Y, Lee PY, Reeves WH. (2010) Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch. Immunol. Ther. Exp. (Warsz). 58:355–64.CrossRefGoogle Scholar
  4. 4.
    Stone RC, et al. (2012) Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons. Arthritis Rheum. 64:788–98.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Yang L, Feng D, Bi X, Stone RC, Barnes BJ. (2012) Monocytes from Irf5−/− mice have an intrinsic defect in their response to pristane-induced lupus. J. Immunol. 189:3741–50.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hansmann L, Groeger S, von Wulffen W, Bein G, Hackstein H. (2008) Human monocytes represent a competitive source of interferon-alpha in peripheral blood. Clin. Immunol. 127:252–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Kanakoudi-Tsakalidou F, et al. (2014) Simultaneous changes in serum HMGB1 and IFN-alpha levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE: new therapeutic options? Lupus. 23:305–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. (2007) High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 8:492–502.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ahmad-Nejad P, et al. (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32:1958–68.CrossRefPubMedGoogle Scholar
  10. 10.
    Bauer S, et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 98:9237–42.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hemmi H, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Sanjuan MA, et al. (2006) CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J. Cell Biol. 172:1057–68.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Saxena M, Busca A, Pandey S, Kryworuchko M, Kumar A. (2011) CpG protects human monocytic cells against HIV-Vpr-induced apoptosis by cellular inhibitor of apoptosis-2 through the calcium-activated JNK pathway in a TLR9-independent manner. J. Immunol. 187:5865–78.CrossRefPubMedGoogle Scholar
  14. 14.
    Kerkmann M, et al. (2003) Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170:4465–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Shirota H, Klinman DM. (2012) Effect of CpG ODN on monocytic myeloid derived suppressor cells. Oncoimmunology. 1:780–2.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gilliet M, Cao W, Liu YJ. (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8:594–606.CrossRefPubMedGoogle Scholar
  17. 17.
    Salloum R, Niewold TB. (2011) Interferon regulatory factors in human lupus pathogenesis. Transl. Res. 157:326–31.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Li P, et al. (2011) IRF8 and IRF3 cooperatively regulate rapid interferon-beta induction in human blood monocytes. Blood. 117:2847–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Yang H, Ma G, Lin CH, Orr M, Wathelet MG. (2004) Mechanism for transcriptional synergy between interferon regulatory factor (IRF)-3 and IRF-7 in activation of the interferon-beta gene promoter. Eur. J. Biochem. 271:3693–703.CrossRefPubMedGoogle Scholar
  20. 20.
    Delgado-Vega AM, Alarcon-Riquelme ME, Kozyrev SV. (2010) Genetic associations in type I interferon related pathways with autoimmunity. Arthritis Res. Ther. 12 Suppl 1:S2.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Honda K, Taniguchi T. (2006) IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644–58.CrossRefPubMedGoogle Scholar
  22. 22.
    Takaoka A, et al. (2005) Integral role of IRF-5 in the gene induction programme activated by Tolllike receptors. Nature. 434:243–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Steinhagen F, et al. (2013) IRF-5 and NF-kappaB p50 co-regulate IFN-beta and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells. Eur. J. Immunol. 43:1896–906.CrossRefPubMedGoogle Scholar
  24. 24.
    Akahoshi M, et al. (2008) Promoter polymorphisms in the IRF3 gene confer protection against systemic lupus erythematosus. Lupus 17:568–74.CrossRefPubMedGoogle Scholar
  25. 25.
    Schwartzberg PL. (1998) The many faces of Src: multiple functions of a prototypical tyrosine kinase. Oncogene. 17:1463–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Rhee I, Veillette A. (2012) Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat. Immunol. 13:439–47.CrossRefPubMedGoogle Scholar
  27. 27.
    Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. (1991) CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J. Biol. Chem. 266:24249–52.PubMedGoogle Scholar
  28. 28.
    Bonaccorsi I, et al. (2010) The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNalpha production. PLoS One. 5:e15080.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. (1999) Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur. J. Immunol. 29:3160–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Meyaard L. (2008) The inhibitory collagen receptor LAIR-1 (CD305). J. Leukoc. Biol. 83:799–803.CrossRefPubMedGoogle Scholar
  31. 31.
    Meyaard L, et al. (1997) LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 7:283–90.CrossRefPubMedGoogle Scholar
  32. 32.
    Tang X, et al. (2012) Leukocyte-associated Ig-like receptor-1-deficient mice have an altered immune cell phenotype. J. Immunol. 188:548–58.CrossRefPubMedGoogle Scholar
  33. 33.
    Poggi A, Tomasello E, Ferrero E, Zocchi MR, Moretta L. (1998) p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur. J. Immunol. 28:2086–91.CrossRefPubMedGoogle Scholar
  34. 34.
    Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B. (2012) C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc. Natl. Acad. Sci. U. S. A. 109:E3160–7.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Verbrugge A, Ruiter Td T, Clevers H, Meyaard L. (2003) Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment. Int. Immunol. 15:1349–58.CrossRefPubMedGoogle Scholar
  36. 36.
    Xu M, Zhao R, Zhao ZJ. (2000) Identification and characterization of leukocyte-associated Ig-like receptor-1 as a major anchor protein of tyrosine phosphatase SHP-1 in hematopoietic cells. J. Biol. Chem. 275:17440–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J. (1998) Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-kappa B. Cell. Immunol. 185:49–58.CrossRefPubMedGoogle Scholar
  38. 38.
    Elkon KB, Santer DM. (2012) Complement, interferon and lupus. Curr. Opin. Immunol. 24:665–70.CrossRefPubMedGoogle Scholar
  39. 39.
    Lood C, et al. (2009) C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 60:3081–90.CrossRefPubMedGoogle Scholar
  40. 40.
    Yamada M, et al. (2004) Complement C1q regulates LPS-induced cytokine production in bone marrow-derived dendritic cells. Eur. J. Immunol. 34:221–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Santer DM, et al. (2010) C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J. Immunol. 185:4738–49.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Byrne JC, et al. (2012) Genetics of SLE: functional relevance for monocytes/macrophages in disease. Clin. Dev. Immunol. 2012:582352.Google Scholar
  43. 43.
    Izaguirre A, et al. (2003) Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74:1125–38.CrossRefPubMedGoogle Scholar
  44. 44.
    Hooks JJ, et al. (1979) Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301:5–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Banchereau J, Pascual V. (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 25:383–92.CrossRefPubMedGoogle Scholar
  46. 46.
    Omagari K, et al. (2003) Anti-extractable nuclear antigens (ENA) antibodies in patients with chronic hepatitis C before and after treatment with interferon. Autoimmunity. 36:269–73.CrossRefPubMedGoogle Scholar
  47. 47.
    Ma CY, et al. (2012) Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol. Int. 32:395–402.CrossRefPubMedGoogle Scholar
  48. 48.
    Olde Nordkamp MJ, et al. (2014) Leukocyte-associated Ig-like receptor-1 is a novel inhibitory receptor for surfactant protein D. J. Leukoc. Biol. 96:105–11.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  1. 1.Center for Autoimmune and Musculoskeletal DiseasesFeinstein Institute for Medical ResearchManhassetUSA

Personalised recommendations